pharma QA – Page 31 – Pharma.Tips

Biologic filter integrity failure during CPV trending review: single-use systems risk controls, leachables review, and supplier oversight actions

Understanding and Investigating Biologic Filter Integrity Failures in CPV Trending Reviews In the landscape of pharmaceutical manufacturing, maintaining the integrity of biologic filters is vital for ensuring product quality and…

Supply interruption risk during small-batch manufacturing: CAPA with limited data sets

“`html Investigation of Supply Interruption Risks in Small-Batch Manufacturing In the realm of pharmaceutical manufacturing, particularly within small-batch environments, the integrity of supply chains is paramount. Suppose a facility identifies…

Biologic host cell protein (HCP) OOS after upstream media/raw material change: patient safety impact assessment and batch disposition governance

Managing Out-of-Specification (OOS) Host Cell Proteins (HCP) after Changes in Upstream Media and Raw Materials In the world of pharmaceutical manufacturing, quality assurance is paramount, particularly regarding biologic products. An…

Specification justification gap during inspection readiness: risk-based GMP justification

Identifying and Addressing Specification Justification Gaps During Inspection Readiness In the realm of pharmaceutical manufacturing, ensuring compliance with Good Manufacturing Practices (GMP) is critical, especially during inspection readiness scenarios where…

Biologic bioburden excursion pre-sterile filtration after filling line intervention: CAPA package with CQA/CPP risk assessment and effectiveness verification

Addressing Biologic Bioburden Excursion Pre-Sterile Filtration Following a Filling Line Intervention In the realm of pharmaceutical manufacturing, biologic products are susceptible to bioburden excursions that can lead to increased risks…

Stability failure with limited batches during regulatory review: CAPA with limited data sets

Addressing Stability Failures in Limited Batches during Regulatory Reviews When stability failures occur in limited batches under regulatory scrutiny, it can present significant challenges for pharmaceutical manufacturers. The implications not…

Biologic upstream yield drop (OOT) during FDA/EMA inspection readiness: viral safety and contamination response plan with inspection-ready evidence

Addressing the Drop in Biologic Upstream Yields During FDA/EMA Readiness: A Comprehensive Investigation In the highly regulated field of pharmaceutical manufacturing, especially in the production of biologics, encountering a drop…

Method variability OOS during regulatory review: CAPA with limited data sets

Investigation of Method Variability OOS During Regulatory Review: Effective CAPA with Limited Data Sets In pharmaceutical manufacturing, method variability leading to Out of Specification (OOS) results can occur even during…

Biologic upstream yield drop (OOT) during commercial manufacturing campaign: CAPA package with CQA/CPP risk assessment and effectiveness verification

Addressing the Root Causes of Biologic Upstream Yield Drop during Commercial Manufacturing Campaigns In the highly regulated field of pharmaceutical manufacturing, particularly in the production of biologics, maintaining optimal yield…

Method variability OOS during small-batch manufacturing: FDA/EMA communication strategy

Handling Method Variability OOS in Small-Batch Manufacturing: An Investigation Guide In pharmaceutical manufacturing, particularly in the production of orphan drugs, achieving consistency is critical to meeting regulatory standards. One common…

Biologic stability failure (real-time/accelerated) during CPV trending review: viral safety and contamination response plan with inspection-ready evidence

Addressing Biologic Stability Failures During CPV Trending Reviews In the realm of pharmaceutical manufacturing, the assessment of biologic stability is critical for ensuring product quality and safety. Stability failures, particularly…

Method variability OOS during lifecycle management: CAPA with limited data sets

Method Variability and Out of Specification (OOS) Investigations in Lifecycle Management In pharmaceutical manufacturing, out of specification (OOS) results pose significant challenges, particularly when related to method variability. This problem…